Success Metrics

Clinical Success Rate
100.0%

Based on 1 completed trials

Completion Rate
100%(1/1)
Active Trials
2(22%)
Results Posted
0%(0 trials)

Phase Distribution

Ph phase_3
3
33%
Ph phase_2
3
33%
Ph phase_1
3
33%

Phase Distribution

3

Early Stage

3

Mid Stage

3

Late Stage

Phase Distribution9 total trials
Phase 1Safety & dosage
3(33.3%)
Phase 2Efficacy & side effects
3(33.3%)
Phase 3Large-scale testing
3(33.3%)

Highest Phase Reached

Phase 3

Trial Status & Enrollment

Completion Rate

50.0%

1 of 2 finished

Non-Completion Rate

50.0%

1 ended early

Currently Active

2

trials recruiting

Total Trials

9

all time

Status Distribution
Active(7)
Completed(1)
Terminated(1)

Detailed Status

Not yet recruiting5
Recruiting2
Completed1
Withdrawn1

Development Timeline

Analytics

Development Status

Total Trials
9
Active
2
Success Rate
100.0%
Most Advanced
Phase 3

Trials by Phase

Phase 13 (33.3%)
Phase 23 (33.3%)
Phase 33 (33.3%)

Trials by Status

recruiting222%
not_yet_recruiting556%
completed111%
withdrawn111%

Recent Activity

2 active trials
Showing 5 of 9
not_yet_recruitingphase_2

Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma

NCT07554482
completedphase_1

HCW9218 for Advanced Pancreatic Cancer

NCT05304936
recruitingphase_3

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

NCT07459296
not_yet_recruitingphase_3

A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer

NCT07383922
not_yet_recruitingphase_3

Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma

NCT07385079
View all 9 trials

Clinical Trials (9)

Showing 9 of 9 trials
NCT07554482Phase 2

Selinexor Combined With Reduced-Dose Radiotherapy For Early-Stage Extranodal NK/T-Cell Lymphoma

Not Yet Recruiting
NCT05304936Phase 1

HCW9218 for Advanced Pancreatic Cancer

Completed
NCT07459296Phase 3

Becotatug Vedotin Plus Sintilimab in Locoregionally Advanced NPC

Recruiting
NCT07383922Phase 3

A Study of FG-M108+Chemotherapy vs Placebo+Chemotherapy in Claudin18.2-positive Pancreatic Cancer

Not Yet Recruiting
NCT07385079Phase 3

Anlotinib Plus Immunotherapy and Chemoradiotherapy for High-Risk Nasopharyngeal Carcinoma

Not Yet Recruiting
NCT07235202Phase 1

A Study of MR001 Combined With Chemotherapy in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma (PDAC) After First-line Therapy

Recruiting
NCT07189793Phase 2

Toripalimab ± Sequential Intravesical Gemcitabine-Mitomycin C for BCG-Unresponsive/-Intolerant High-Risk NMIBC: Open-Label Randomized Phase 2 Study

Not Yet Recruiting
NCT07129772Phase 2

Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal Carcinoma

Not Yet Recruiting
NCT05251038Phase 1

Study of Sotorasib Combined With Chemotherapy for Second Line Treatment of Pancreas Cancer

Withdrawn

All 9 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
9